Videos

Paul Richardson, MD, delves into some of the studies significantly impacting the multiple myeloma treatment landscape and outcomes for patients.

This segment delves into the management of a case of moderate cGvHD involving the skin, eyes, and mouth, with a focus on the use of Belumosudil based on the ROCKstar trial data.

This segment delves into the management of a case of moderate cGvHD involving the skin, eyes, and mouth, with a focus on the use of Belumosudil based on the ROCKstar trial data.

Rebecca A. Shatsky, MD, looks to the future of HER2+ breast cancer treatment, highlighting unmet needs in the therapeutic space.

Sumanta Kumar Pal, MD, FASCO, presents the case of a 66-year-old man with metastatic renal cell carcinoma, and the panel provides comprehensive insights on treatment decisions, highlighting the NCCN Guidelines.

A panel of 4 experts on renal cell carcinoma introduce themselves and discuss IMDC risk stratification criteria and the evolution of the treatment landscape.

Lova Sun, MD, MSCE, discusses resistance mechanisms against targeted agents for the treatment of thyroid cancer.

A medical professional outlines the goals and challenges of communicating with his patient, emphasizing the importance of setting realistic expectations for halting disease progression and potentially achieving some degree of disease reversibility, while also exploring the roles of first-line and second-line therapies in the management of chronic graft versus host disease.

Yi-Bin Chen, MD, presents a patient case, detailing the symptomology and pathology of graft versus host disease, such as dry eyes, dry mouth, and difficulty swallowing, while also addressing steroid dependence as an indication for initiating second-line therapy.

Lucia Masarova, MD, PhD, discusses some of the latest updates across myeloproliferative neoplasms.

Dr. Schiller will discuss the limitations of current treatment options for BPDCN in elderly transplant-ineligible patients and the emerging BPDCN research and data that they are most interested in to improve outcomes in this specific patient population.

Dr. Schiller will discuss how their treatment approach would differ for a 74-year-old BPDCN patient with only well-controlled type 2 diabetes as a comorbidity and an ECOG performance status of 0.

Dr. Schiller will discuss the red flag symptoms that increase suspicion of BPDCN, the process for diagnosis, and any challenges with differential diagnosis. Dr. Schiller will also provide strategies and resources to improve community recognition and diagnosis of this rare disease.

Dr. Schiller will discuss the limitations of currently available BPDCN treatments, the historical use of chemotherapy regimens and their potential to address unmet needs, and effective strategies for managing the financial burden and ensuring access to tagraxofusp for BPDCN patients.

Dr. Schiller will discuss the key factors that make the transplant ineligible BPDCN patient population more difficult to treat, the major goals of therapy for these patients, and how the mechanism of action of tagraxofusp suggests potential efficacy in BPDCN.

Dr. Schiller will discuss the key clinical and pathologic features that distinguish BPDCN from other malignancies, as well as the potential differential diagnoses that share a similar immunophenotype.

Discussing how various treatments for chronic GvHD impact quality of life in terms of disease response and side effects.

Exploring general principles and practices for monitoring and mitigating adverse events in patients with chronic GvHD treated with systemic agents, and determining when dose modification or treatment discontinuation is warranted.

Rahul Banerjee, MD, discusses new frontiers in the treatment of multiple myeloma with CAR T-cell therapy.

Alex Chehrazi-Raffle, MD, discusses findings from a real-world analysis of adjuvant treatment in bladder cancer presented at ASCO GU.

This segment explores the management of steroid-refractory cGvHD, highlighting the data from clinical trials on agents like ibrutinib and ruxolitinib. The discussion delves into the potential benefits, risks, and optimal patient selection for these novel therapies.

This segment focuses on the key considerations for diagnosing cGvHD and the initial treatment approaches, including the use of corticosteroids and combination therapies. The discussion covers factors that guide the decision-making process, such as organ involvement, severity of symptoms, and response to initial therapy.

Yara Abdou, MD, looks back on what have been the biggest challenges in treating HER2-positive breast cancer over the past 5-10 years.

Dr Shatsky provides clinical insights on treatment sequencing for patients undergoing treatment for HER2-positive breast cancer.

An expert on HER2+ breast cancer discusses exciting advancements in the treatment landscape, highlighting the DESTINY-Breast03 trial and trastuzumab deruxtecan.

Lova Sun, MD, MSCE, discusses targeted therapies for NTRK and RET alterations in thyroid cancers.

David L. Bartlett, MD, discusses some of the most recent developments that have been seen in genomic testing for patients with cancer in recent years.

Yanghee Woo, MD, discusses a debate which focused on determining the best neoadjuvant therapy for patients with gastroesophageal junction adenocarcinoma.

Discussing the key safety issues observed with ruxolitinib treatment in the REACH-3 trial and evaluating the risk/benefit profile for patients with steroid-refractory chronic GvHD.

Examining the efficacy and safety findings from recent studies on ibrutinib, ruxolitinib, and Belumosudil for chronic GvHD, and their implications for treatment choices.